VEGFA and renal cell adenocarcinoma: RCC represents a prototype of an AA-therapy sensitive tumor due to its unique molecular pathogenesis where inactivation of the Von Hippel–Lindau (VHL) tumor suppressor gene triggers a cascade of pro-angiogenic and thus tumor promoting events, resulting in an increase of growth factors such as VEGF advancing tumor growth, proliferation as well as migration of endothelial cells.